News

Video

ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia

Outcomes from high myopia LASIK using the Teneo laser platform demonstrate strong visual stability and patient satisfaction, with reduced dysphotopsias and minimal reliance on cycloplegia or nomograms.

Karl G. Stonecipher, MD, presented data on LASIK outcomes in high myopia using an advanced excimer laser system with an aspheric ablation algorithm at the 2025 American Society of Cataract and Refractive Surgery annual meeting, held April 25 to 28 in Los Angeles, California. The study focused on patients averaging -5.6 D of myopia, with some as high as -8 D. Stonecipher emphasized both visual outcomes and patient-reported satisfaction.

“What were the key figures that we were kind of excited about with regards to outcomes in this particular arm of the trial?” he asked. “We’re really looking at high myopia. So we're talking about -8.”

One of the features of the laser platform, the Teneo, is its ease of use and speed, he noted. “It’s a GUI interface, which is really easy to understand. My staff loves that. It's very comfortable for the patient, and it's extremely fast at 1.2 seconds per diopter,” said Stonecipher. These attributes, he noted, contributed to patient satisfaction rates of 98% to 99%.

On the topic of visual quality, particularly dysphotopsias, he reported significant improvement compared with earlier platforms. “Patients come in, we don't see as much glare and halos... we show improvements across all platforms at this high level, and we don't see dysphotopsias like we saw with a lot of those earlier platforms.” The PROWL questionnaire was used to assess subjective outcomes.

The laser’s simplicity was another highlight: “We just put the manifest in the box. This is not nomogrammed information... you had 20/20, 20/25 level of vision that was stable in the high 90 range.”

Stonecipher concluded by noting, “It’s a very convenient laser,” adding that patients are satisfied in varied lighting conditions and daily activities.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.